Pfizer objects to NICE methods in leukaemia drug rejectionNICE has caused controversy by rejecting Pfizer’s Besponsa – a blood cancer drug that can give patients the Share XPfizer objects to NICE methods in leukaemia drug rejectionhttps://pharmaphorum.com/news/pfizer-questions-nice-methods-besponsa/
Pfizer’s fast-tracked leukaemia candidate could rival CAR-TsAntibody-drug conjugate with FDA gets six-month review. Share XPfizer’s fast-tracked leukaemia candidate could rival CAR-Tshttps://pharmaphorum.com/news/pfizer-files-leukaemia-antibody-us/